Septerna (SEPN) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
UroGen Pharma (URGN) has outperformed Septerna (SEPN) over the past year, gaining 124.3% versus a gain of 64.1%. UroGen Pharma is the larger company by market cap ($1.80 billion vs $1.79 billion), about 1.0 times the size, while Septerna is growing revenue faster (+4174.5% vs +21.4%). Septerna converts more of its revenue into profit, with a net margin of -106.4% versus -139.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SEPN | URGN |
|---|---|---|
| Share price | $38.37 | $36.83 |
| Market cap | $1.79B | $1.80B |
| 1-day change | +3.98% | -0.41% |
| YTD return | +32.35% | +57.26% |
| 1-year return | +64.07% | +124.30% |
| 5-year return | — | +116.39% |
| Forward P/E | — | 13.18 |
| EPS (TTM) | $-0.56 | $-1.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $45.95M | $109.79M |
| Revenue growth (YoY) | +4174.51% | +21.45% |
| Net income (latest FY) | $-48.88M | $-153.49M |
| Gross margin | — | 88.66% |
| Operating margin | -148.63% | -113.73% |
| Net margin | -106.37% | -139.81% |
| 52-week high | $51.10 | $50.81 |
| 52-week low | $17.55 | $15.86 |
| Distance from 52-week high | -24.91% | -27.51% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +41.31% | +62.91% |
| Average volume | 390.66K | 849.01K |
| Shares outstanding | 46.68M | 48.88M |
| Employees | 123 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- URGN has outperformed SEPN by 60.2 percentage points over the past year.
- Septerna is more profitable, keeping -106.4 cents of every revenue dollar as net income versus -139.8 cents for UroGen Pharma.
- Septerna grew revenue faster in its latest fiscal year (+4174.51% vs +21.45%).
About Septerna
SEPN stock →Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 123 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
SEPN vs URGN FAQ
Which is bigger, Septerna or UroGen Pharma?
UroGen Pharma (URGN) is larger, with a market capitalization of $1.80B compared with $1.79B for Septerna (SEPN).
Which stock has performed better over the past year, SEPN or URGN?
URGN returned +124.30% over the past 12 months, compared with +64.07% for SEPN (price return, excluding dividends). Past performance does not predict future results.
Are Septerna and UroGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.